amlodipine besilate / Generic mfg. - LARVOL DELTA

Amlodipine Besylate-Folic Acid demonstrates superior efficacy to Enalapril Maleate-Folic Acid in treating H-type hypertension. (PubMed, Am J Transl Res) - "Amlo-FA is effective in treating HTH."

Journal • Cardiovascular • Diabetes • Dyslipidemia • Hypertension • Metabolic Disorders

Hydroxypropyl-β-cyclodextrin-assisted Acetonitrile Field-amplified Stacking in Capillary Electrophoresis Enabling Ultra-Trace Quantification of Amlodipine Enantiomers in Human Plasma. (PubMed, J Sep Sci) - "Amlodipine besylate, a third-generation dihydropyridine calcium channel modulator, is routinely prescribed as a racemic mixture in the clinical management of arterial hypertension and ischemic chest pain...For (R)- and (S)-amlodipine, linear calibration was achieved across the range 0.2475-19.80 ng/mL and met the commonly accepted bioanalytical criteria. Comparative pharmacokinetic evaluation demonstrated no statistically significant differences between the concentration-time profiles obtained with the proposed CE method and those generated by a reference liquid chromatography-tandem mass spectrometry assay, confirming the accuracy and reliability of the developed procedure for routine therapeutic drug monitoring."

Journal • Acute Myelogenous Leukemia • Cardiovascular • Hypertension • Pain • Pulmonary Arterial Hypertension

Bioequivalence Study of Sacubitril Alisartan Amlodipine Tablets (clinicaltrials.gov) - P1 | N=60 | Not yet recruiting | Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.

New P1 trial • Cardiovascular • Hypertension

Amlodipine besylate, a Dihydropyridine derivative as a Tubulin polymerization inhibitor. (PubMed, Cell Biochem Biophys) - No abstract available

Journal • Oncology

Spectroscopic methods for the simultaneous determination of amlodipine besylate and Hydrochlorothiazide in their binary mixture and pharmaceutical dosage form. (PubMed, Sci Rep) - "Amlodipine besylate's linearity range was 5-30 µg/mL, whereas hydrochlorothiazide's was 3-18 µg/mL reaching limits of detection of 1.238, 0.906, 0.825, 0.540, 0.779 and 0.805 µg/mL, respectively for all the proposed methods. The proposed methods were validated in accordance with ICH international guidelines, including full statistical analysis and comprehensive environmental evaluation using multiple assessment tools as The Analytical GREEnness Calculator, the Modified Green Analytic Procedure Index, spider diagram, and green analytical selection tool."

Journal

SSY Group Limited Obtains Approval for Drug Production and Registration for Perindopril Arginine and Amlodipine Besylate Tablets (Market Screener) - "The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Perindopril Arginine and Amlodipine Besylate Tablets (III) (perindopril arginine 10mg, amlodipine besylate 5mg) from National Medical Products Administration of China, being under type 4 chemical drug and regarded as passing the consistency evaluation. Perindopril Arginines and AmlodipineBylate Tablet is a compound preparation which is mainly used in adult patients whose hypertension is not adequately controlled by monotherapy, or as an alternative therapy for primary hypertension which is under control by combination therapy with the same dose level of perindopril and amlodipine."

ANDA • Hypertension

Fabrication and characterization of taste-masked core-shell nanofibre mats for dual drug delivery of antihypertensives in pediatrics. (PubMed, Int J Pharm) - "With pediatric hypertension on the rise worldwide, this study investigated the use of electrospinning to create a novel taste-masked, fixed-dose combination of lisinopril dihydrate (LIS) and amlodipine besylate (AML) for paediatric use. The e-tongue mean sensor response plot showed the nanofibre mats achieved a statistically significant enhanced taste-masking (p < 0.0001) compared to raw amlodipine which registered a high bitterness reading of 87 mV. This study therefore indicates that coaxial electrospinning may be used to produce a fixed-dose taste masked nanofibre mat of LIS and AML that can potentially be used to improve adherence in children."

Journal • Acute Myelogenous Leukemia • Cardiovascular • Gastrointestinal Disorder • Hypertension • Pediatrics

Suspected S-1-Induced Rhabdomyolysis during Adjuvant Chemotherapy after Breast Cancer Surgery-A Case Report (PubMed, Gan To Kagaku Ryoho) - "We present a case of suspected S-1-induced rhabdomyolysis in a 56-year-old woman with a history of hypertension and dyslipidemia, who was taking amlodipine besilate and pravastatin sodium...Following dose-dense EC therapy and discontinuation of docetaxel owing to drug-induced pneumonitis, she began adjuvant therapy with letrozole and S-1...Given the temporal relationship and resolution upon drug withdrawal, S-1 was considered the likely causative agent. Although extremely rare, clinicians should be aware of the potential for S-1-induced rhabdomyolysis and monitor for muscle-related symptoms during treatment."

Journal • Breast Cancer • Cardiovascular • Dyslipidemia • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Hypertension • Metabolic Disorders • Musculoskeletal Pain • Oncology • Pain • Pneumonia • Solid Tumor • HER-2

Factors Affecting Tablet Disintegration by Immersion in Food Thickener Solution. (PubMed, Cureus) - "When Blopress® tablets containing disintegrants were immersed in a xanthan gum-based thickener solution, the disintegration time was prolonged by approximately 80-300 s, and linear regression analysis showed that this prolongation was significant. Meanwhile, the disintegration time of Norvasc® tablet (5 mg), which also contains a disintegrant, was 42 s without immersion and extended to 187 s after immersion in a thickening solution of xanthan gum for 30 min. Furthermore, the starch-based thickener solution did not affect tablet disintegration regardless of the presence or absence of disintegrants."

Journal

Oxaliplatin and amlodipine combination induced reversible Brugada phenocopy: A case report. (PubMed, Medicine (Baltimore)) - "In this paper, we analyzed the possible mechanism of oxaliplatin combined with amlodipine induced reversible type 1 BrP, so as to provide clinical reference for the safe medication of chemotherapy patients. At the same time, it is suggested that clinicians should pay attention to the risk of synergistic inhibition of ion channels when chemotherapy drugs are combined with antihypertensive drugs, which provides key clinical evidence for reducing the incidence of cardiovascular complications and optimizing multi-drug combination therapy in cancer patients."

Journal • Cardiovascular • Colorectal Cancer • Genetic Disorders • Oncology • Rectal Cancer • Solid Tumor

Biowaiver monograph for immediate-release solid oral dosage forms: Amlodipine Besylate. (PubMed, J Pharm Sci) - "With a favorable safety profile and a wide therapeutic index, the overall evidence leads to a conservative classification of amlodipine besylate to BCS III. Thus, IR products containing this drug can be candidates for the BCS-based biowaiver, thereby enabling substitution of surrogate in vitro methods for in vivo BE approval of multisource products."

Journal • Cardiovascular • Coronary Artery Disease • Hypertension

Development of a Stable Microemulsion - Based Delivery of Amlodipine Besylate: A Promising Approach for Topical Treatment of Anal Fissures. (PubMed, Pharm Dev Technol) - "In vitro safety evaluations confirmed a non - irritant profile and low acute toxicity.Compared with other reported topical CCB preparations, this AMD - loaded ME provides superior physicochemical stability, reproducible permeation, and dermal compatibility. These results establish a translational platform for future GMP - scale validation and clinical assessment in AF management."

Journal • Gastrointestinal Disorder • Pain

The effect of amlodipin, a calcium channel blocker, on tendon healing: an experimental study in rat model of Achilles tendon injury. (PubMed, Eur J Trauma Emerg Surg) - "Amlodipine appears to accelerate and enhance Achilles tendon healing by promoting fibroblastic proliferation, angiogenesis, and biomechanical strength, while reducing inflammation. These findings suggest a potential role for amlodipine as a pharmacologic adjunct in tendon repair; however, further mechanistic and clinical studies are warranted."

Journal • Preclinical • Inflammation

Impact of Shared Treatment Decision Making Between Physicians and Patients on Treatment Satisfaction in Hypertension (ISPOR-EU 2025) - "Subjects were patients diagnosed with hypertension who had been prescribed amlodipine besylate within the past year... A treatment drug selection process where physicians present multiple options and patients select is potentially associated with higher treatment satisfaction than physician-prescribed treatment. Enhanced communication between physicians and patients may contribute to improved satisfaction. Further analysis is warranted to elucidate additional factors that may influence patient satisfaction."

Clinical • Cardiovascular • Hypertension

pH-Switchable molecularly imprinted polymers for enantioselective recognition and separation of (S)-amlodipine besylate from its chiral counterpart. (PubMed, Anal Methods) - "Systematic binary competitive experiments with S-ADB and R-ADB at varying molar ratios conclusively established the polymer's excellent enantiomeric discrimination capability, showing minimal interference even when the R-ADB concentration was 4 times higher than that of S-ADB-highlighting its efficacy in addressing the key challenge of chiral separation under competitive conditions. The results demonstrate the promising application of pH-switchable MIPs as a novel platform technology for high-precision chiral resolution and pharmaceutical-grade enantiomer purification."

Journal

Bioequivalence Study of Sacubitril Alisartan Amlodipine Tablets and Sacubitril Alisartan Calcium Tablets Combined with Amlodipine Besylate Tablets (ChiCTR) - P=N/A | N=40 | Not yet recruiting | Sponsor: The Second Affiliated Hospital of Guangzhou Medical University; The Second Affiliated Hospital of Guangzhou Medical University

New trial • Cardiovascular • Hypertension

Coated Zein Polymeric Nanoparticles Loaded with Amlodipine as a Repurposed Antibacterial Ocular Cure for MRSA-Induced Infection: Optimization, In Vitro, Ex Vivo, and In Vivo Assessments. (PubMed, Pharmaceutics) - "Background: Amlodipine besylate (AML) is recognized as a calcium channel blocker curative for hypertension...In vitro microbial assay alongside the corneal in vivo microbial and histological pathology evaluation proved the efficacy of amlodipine as an antibacterial agent. These findings highlighted that the prepared AML-ZNs-Alg eyedrop can be a promising system as an antibacterial therapy."

Journal • Preclinical • Acute Myelogenous Leukemia • Cardiovascular • Hypertension • Infectious Disease

The Development and Characterization of Layered Pellets Containing a Combination of Amorphized Amlodipine Besylate and Hydrochlorothiazide Using a High-Shear Granulator. (PubMed, Pharmaceuticals (Basel)) - "Furthermore, the drug combination in layered pellets was partially amorphized with a lower crystallinity percentage, a lower intensity, a broadening of the hydrochlorothiazide melting peak, and a higher cumulative release of both drugs with good stability, except pellets with a molar ratio of 1:2 that were recrystallized with a higher crystallinity percentage of 79.9%. Modifying the physical form and dissolution behavior of the hydrochlorothiazide and amlodipine besylate combination was achieved by single-step layering pelletization."

Journal

Foamable pluroleosomes system loaded with amlodipine as a repurposed antibacterial topical formulation against MRSA-induced infection; optimization, in-vitro, ex-vivo, and in-vivo studies. (PubMed, Int J Pharm X) - "Amlodipine besylate (AML) is a renowned antihypertensive drug currently acknowledged for having antibacterial activity...In vitro microbiological assay, besides the in vivo microbiological and histopathological studies employing a wound healing model, validated the antibacterial efficacy of amlodipine. Those outcomes demonstrated that the prepared pluroleosome foam system of AML is a competent candidate for combating topical bacterial infection."

Journal • Preclinical • Acute Myelogenous Leukemia • Infectious Disease

Development and Evaluation of a Modified Fixed-Dose Combination Antihypertensive Tablet Containing S-Amlodipine Besylate: A Bioequivalence and Stability Study. (PubMed, Pharmaceutics) - "In vitro dissolution testing demonstrated pharmaceutical equivalence with the marketed reference FDC, and an in vivo pharmacokinetic study confirmed bioequivalence. These results suggest that the newly developed S-amlodipine besylate-containing FDC tablet is a viable alternative to existing olmesartan/amlodipine/hydrochlorothiazide combinations, offering comparable efficacy and pharmacokinetic properties with the potential for improved safety and patient adherence in the management of hypertension."

Journal • Cardiovascular • Hypertension

Effects of Two Allisartan Isoproxil-Based Antihypertensive Therapies on Sexual Function and Blood Pressure in Male Hypertensive Patients: A Single-Center, Open-Label, and Randomized Controlled Trial. (PubMed, J Clin Hypertens (Greenwich)) - "This study evaluated the effects of allisartan isoproxil combined with amlodipine besylate tablets (Group A+C) or metoprolol succinate extended-release tablets (Group A+B) on sexual function and nighttime blood pressure (nBP) in 130 male patients with essential hypertension (EH). It was concluded that combined antihypertension of allisartan isoproxil with amlodipine besylate tablets improved sexual function in male hypertensive patients in terms of the ITS, IS, OF, and OS, but there was no significant improvement in EF and SD. Both combined antihypertensive regimens were effective in lowering BP, but allisartan isoproxil combined with amlodipine besylate tablets demonstrated more advantageous in lowering DBP and nBP."

Clinical • Journal • Cardiovascular • Hypertension

Antimicrobial Stability, pH, and Physical Appearance of Cardiovascular Drug Suspensions in SyrSpend® SF PH4: A Complementary Evaluation. (PubMed, Int J Pharm Compd) - "Nine oral formulations of seven cardiovascular drug suspensions were included: amlodipine (as besylate) 1.0 mg/mL, enalapril maleate 1.0 mg/mL, hydrochlorothiazide 2.0 and 5.0 mg/mL, lisinopril (as dihydrate) 1.0 mg/mL, metoprolol tartrate 10.0 mg/mL, pentoxifylline 20.0 mg/mL, and spironolactone 2.0 and 2.5 mg/mL. All formulations met USP criteria for antimicrobial effectiveness, while maintaining stable pH values and no relevant changes in physical appearance throughout the study. These results, when combined with previously demonstrated chemical stability (HPLC), confirm that SyrSpend® SF PH4 is a robust and reliable vehicle for preservative-free extemporaneous oral liquid formulations, supporting its safe use within USP-compliant BUD limits."

Journal • Cardiovascular • Pediatrics

Classical and alternative renin-angiotensin-aldosterone systems in a feline remnant kidney model. (PubMed, Am J Vet Res) - "Serum was collected at 2 time points 6 months apart from young-adult purpose-bred cats with remnant kidney model-induced CKD (n = 15; 6 hypertensive, chronically treated with amlodipine besylate) and at a single time point from young-adult community-owned healthy cats (n = 15)...Evidence of RAAS activation at the level of circulating angiotensin peptides was not found in cats with induced CKD. Although circulating aldosterone was increased in cats with induced CKD, this was not likely driven by an increase in other circulating RAAS components."

Journal • Nephrology • Renal Disease

Dual-platform integration of HPTLC and firefly algorithm-optimized chemometrics with hammersley sequence sampling for simultaneous quantification of bisoprolol, amlodipine, and mutagenic impurity 4-hydroxybenzaldehyde. (PubMed, BMC Chem) - "This study presents the first multicolor analytical platform for concurrent determination of bisoprolol fumarate (BIP), amlodipine besylate (AML), and 4-hydroxybenzaldehyde (HBZ), a Class 3 mutagenic impurity in BIP requiring strict regulatory monitoring. Successful application to pharmaceutical dosage forms validated the methods' practical utility. This work establishes a new paradigm in sustainable pharmaceutical analysis, demonstrating how algorithmic optimization and environmental consciousness can synergistically advance analytical science while meeting stringent regulatory requirements."

Journal • Acute Myelogenous Leukemia

Effectiveness of single-pill combination olmesartan/amlodipine/hydrochlorothiazide therapy in patients with apparent resistant hypertension. (PubMed, J Hum Hypertens) - "After treatment with olmesartan medoxomil/amlodipine besylate/hydrochlorothiazide for 24 weeks, adults with apparent resistant hypertension had significantly reduced systolic BP and approximately 80% achieved target BP. SPC therapy may improve adherence in patients with pseudo-resistant hypertension and is a potentially effective treatment for resistant hypertension."

Journal • Cardiovascular • Hypertension